Can Borui Biotech stand out in the treatment of lymphoma with the launch of its first biologically innovative drug, Zebedumab?
AD |
21st Century Business Herald reporter Zhu Yiyi reports from ShanghaiThe launch of this new drug is not only a major milestone in the development of Brilliant Biology, but also provides new treatment options for domestic lymphoma patients.Multiple indicators with significant clinical efficacyAccording to public information, lymphoma is one of the common hematological malignancies
21st Century Business Herald reporter Zhu Yiyi reports from Shanghai

The launch of this new drug is not only a major milestone in the development of Brilliant Biology, but also provides new treatment options for domestic lymphoma patients.
Multiple indicators with significant clinical efficacy
According to public information, lymphoma is one of the common hematological malignancies. At present, the incidence rate of lymphoma in China is about 6.68/100000 people, with more than 100000 new cases every year. Among them, B-cell non Hodgkin lymphoma is one of the common types, and the number of cases and deaths are increasing year by year.
In addition, the market prospects for CD20 targets are broad.
According to Frost&Sullivan's report, in 2020, the market size of anti CD20 monoclonal antibodies in China will be 3.5 billion yuan, which is expected to reach 9.8 billion yuan and 22 billion yuan in 2025 and 2030, respectively. The compound annual growth rate from 2020 to 2025 is 23.1%, and the compound annual growth rate from 2025 to 2030 is 17.5%.
Against the above background, numerous pharmaceutical companies are vying to layout around the CD20, a "old but new" target.
In the face of fierce market competition, what are the advantages of Borui Bio's Zebedumab? Can we break through the tight encirclement?
"In 2007, we cooperated with Academician Shen Beifen, an academician of the CAE Member and an academic leader of molecular immunology, and his team to develop Zebetumab. After 16 years of research and development, the biological innovative drug was finally approved for marketing in 2023." On the sidelines of the national marketing conference of Anruixizebetumab, Wang Haibin, CEO of Braui Biology, pointed out in an interview with reporters from 21st Century Business Herald.
According to Wang Haibin, "Compared to other anti CD20 monoclonal antibody products, the cytotoxic effect (ADCC) mediated by Zebedizumab antibody is stronger, and it has a larger steady-state distribution volume, which can produce a more lasting clearance effect on B cells, thereby exerting better drug effects.
The commercialization progress and indication expansion of Zebedizumab are receiving attention
At this stage, Wang Haibin revealed that he will provide patients with greater access through charitable assistance.
For the development plan of other indications of zebetozumab, Wang Haibin said that the company would further expand the relevant indications of zebetozumab, "such as developing relevant indications for some subtypes of other B-cell lymphoma; in the future, we will also promote the field of autoimmunity, including developing relevant indications for primary immune thrombocytopenia (ITP), Rheumatoid arthritis (RA) and nephrology".
Focusing on self immunity and tumor pipelines
As an innovative biopharmaceutical enterprise, Borui Biotech focuses on the fields of autoimmune and tumor treatment, and differentiates its innovation pipeline. At present, the company has more than 20 main research products, of which more than 10 have entered the clinical stage, and 6 have been commercialized and listed.
The shareholders of Borui Biotech include well-known investment institution Taimeng Investment, A-share listed company Haizheng Pharmaceutical (600267. SH), and Taizhou State owned Asset Investment Group Co., Ltd.
In addition, BRY812, a class 1 new drug of Brevibios, is a new anti LIV-1ADC drug for breast cancer and the second targeted LIV-1ADC drug entering the clinical stage in the world.
For more information, please download the 21 Finance APP
Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])
Mobile advertising space rental |
Tag: the of Can Borui Biotech stand out in treatment
Lai Rong High Speed Railway Begins Cold Sliding Test of Contact System
NextProof of concept New Configurable Chip free RFID Strain Sensor
Guess you like
-
S&P Global Sustainability Yearbook 2024: Baidu's Inclusion Highlights the Crucial Role of AI GovernanceDetail
2025-02-19 21:08:50 1
-
Ronshen Refrigerators Lead 2024 Offline Market: Full-Scenario Embedded Refrigerators Drive Consumption UpgradeDetail
2025-02-19 19:12:01 11
-
Lenovo Xiaoxin Pro 2025 Series Unveiled: AI-Powered Evolution for an Upgraded ExperienceDetail
2025-02-19 10:43:34 11
-
The DeepSeek-R1 7B/14B API service is officially launched, offering 1 million free tokens!Detail
2025-02-19 10:18:07 1
-
Baidu's 2024 Financial Report: AI Strategy Drives Revenue Growth, Smart Cloud Leads the Large Model RaceDetail
2025-02-18 19:11:21 1
-
Xiaohongshu's IPO Plans: Rumors of State-Owned Enterprise Investment False, but Valuation Could Reach $20 USD BillionDetail
2025-02-18 10:27:03 1
-
Ulike Launches Three New Hair Removal Devices, Ushering in a New Era of Home Hair RemovalDetail
2025-02-17 22:00:06 11
-
Global Personal Smart Audio Market in 2025: Opportunities and Challenges Amidst Strong GrowthDetail
2025-02-17 15:28:45 1
-
OPPO Find N5: An In-Depth Look at the New Document App and Cross-System ConnectivityDetail
2025-02-17 15:25:26 1
-
Ping An Good Driver's AI-Powered Smart Insurance Planner Wins 2024 Technological Innovation Service Case AwardDetail
2025-02-17 09:36:45 11
- Detail
-
Xiaomi's Electric Vehicles Become a Growth Engine: Over 135,000 Deliveries in 9 Months, Orders Extending 6-7 Months OutDetail
2025-02-16 12:34:46 1
-
Geely Granted Patent for "Smart Charging Robot" Design, Enabling Automated EV ChargingDetail
2025-02-14 16:58:11 1
-
OPPO Find N5: Ushering in the 8mm Era for Foldable Smartphones A Milestone Breakthrough in Chinese Precision ManufacturingDetail
2025-02-14 13:05:02 1
-
Global Semiconductor Market Experiences Strong Growth in 2024: AI-Driven Data Centers Fuel Expansion, Samsung Reclaims Top SpotDetail
2025-02-14 13:00:26 21
-
Douyin's 2025 Spring Festival Consumption Data Report: Livestreaming Significantly Boosts Offline Consumption, Intangible Cultural Heritage and Tourism Emerge as New HighlightsDetail
2025-02-06 10:59:24 11
-
98-inch or 100-inch TV? An In-Depth Analysis of Large-Screen TV Selection ChallengesDetail
2025-02-06 05:24:30 1
-
Hanoi Stadium Drone Disaster: Unveiling the Complex Relationship Between Vietnam and the Sino-Korean Drone MarketDetail
2025-02-05 12:51:51 21
-
Douyin's 2023 Spring Festival Consumption Data Report: A Collision of Robust Consumption and Diversified New Year CustomsDetail
2025-02-05 10:21:17 1
-
Baidu Intelligent Cloud Illuminates China's First Self-Developed 10,000-GPU Cluster, Ushering in a New Era of AI Computing PowerDetail
2025-02-05 09:36:39 11